Pharma Industry News

Lilly’s tirzepatide beats Ozempic in head-to-head type 2 diabetes trial

All three doses of Lilly’s drug demonstrated superior HbA1C and body weight reductions compared to OzempicOriginal Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]